Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Flashback: Top five wildest moments from Elon Musk’s...
Less than half of DOGE-terminated contracts can be...
Jill Biden should have to answer for ‘cover...
DOGE staffing shakeup as Elon Musk hangs up...
State Dept says DOGE’s changes will be permanent...
President Trump teases ‘last day, but not really’...
Trump denounces court’s ‘political’ tariff decision, calls on...
I’m a physician and I’m worried that our...
Inside the late-night drama that led to Trump’s...
Alleged attempt to impersonate White House chief of...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

Senate confirms Dr Marty Makary as Trump’s FDA chief

by admin March 26, 2025
March 26, 2025
Senate confirms Dr Marty Makary as Trump’s FDA chief

President Donald Trump’s choice to lead the Food and Drug Administration (FDA), Johns Hopkins School of Medicine professor Dr. Marty Makary, was confirmed in the Senate on Tuesday.

His confirmation was cemented just hours after he cleared one last procedural test vote earlier in the evening. 

The Senate voted 56-44 to invoke cloture on the nomination prior to his final confirmation.

Makary, a former Fox News medical contributor, went before the Senate Committee on Health, Education, Labor and Pensions (HELP) earlier this month and answered various questions on vaccines, chronic illness, food safety and abortion. 

During his hearing, the nominee faced scrutiny over an FDA vaccine meeting that was reportedly postponed at the last minute. 

‘So if you are confirmed, will you commit to immediately reschedule that FDA Vaccine Advisory Committee meeting to get the expert views?’ Sen. Patty Murray, D-Wash., asked Makary at the time. 

He responded that he ‘would reevaluate which topics deserve a convening of the advisory committee members on [Vaccines and Related Biological Products Advisory Committee] and which may not require a convening.’ 

When this response wasn’t good enough for Murray, Makary flipped the question, telling her to confront the Biden administration. ‘Well, you can ask the Biden administration that chose not to convene the committee meeting for the COVID vaccine booster,’ he said. 

He was referring to the Biden administration in 2021 pushing through FDA approval for a COVID-19 booster for everyone over the age of 18. 

‘The FDA did not hold a meeting of the Vaccines and Related Biological Products Advisory Committee on these actions,’ read a press release at the time, ‘as the agency previously convened the committee for extensive discussions regarding the use of booster doses of COVID-19 vaccines and, after review of both Pfizer’s and Moderna’s EUA requests, the FDA concluded that the requests do not raise questions that would benefit from additional discussion by committee members.’

Committee member Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, criticized the administration’s move, saying, ‘We’re being asked to approve this as a three-dose vaccine for people 16 years of age and older, without any clear evidence if the third dose for a younger person when compared to an elderly person is of value.’

Makary has long been a critic of the administration he will now lead. He wrote an opinion piece in 2021, calling for ‘fresh leadership at the FDA to change the culture at the agency and promote scientific advancement, not hinder it.’

‘We now have a generational opportunity in American healthcare,’ he said at his hearing. ‘President Trump and Secretary Kennedy’s focus on healthy foods has galvanized a grassroots movement in America. Childhood obesity is not a willpower problem, and the rise of early-onset Alzheimer’s is not a genetic cause. We should be, and we will, be addressing food as it impacts our health.’

This post appeared first on FOX NEWS

previous post
With Trump’s blessing, Israel has Hamas terrorists on back foot: ‘Operating in survival mode’
next post
Trump’s pick to lead NIH, Dr. Jay Bhattacharya, confirmed by Senate in party-line vote

You may also like

Vulnerable House Dem dodges question on VP Harris’...

July 24, 2024

Top Democratic super PAC launches massive $50M ad...

July 27, 2024

Biden likely to keep same routine, accomplish ‘nothing’...

July 25, 2024

JONATHAN TURLEY: Why I’m congratulating the Washington Post

October 26, 2024

Trump signs proclamation declaring February 9 ‘Gulf of...

February 10, 2025

The fatal flaw in Kamala Harris’ speech, marred...

October 31, 2024

House GOP braces for government funding chaos as...

September 18, 2024

Trump asks about ‘J-6 Hostages’ in response to...

December 2, 2024

Influential leader of Canada’s Ontario province seeks Trump,...

January 12, 2025

Pope Francis urges Catholic voters to ‘choose the...

September 14, 2024

Recent Posts

  • Flashback: Top five wildest moments from Elon Musk’s DOGE tenure as it comes to an end
  • Less than half of DOGE-terminated contracts can be publicly tracked, only about a quarter of grants: watchdog
  • Jill Biden should have to answer for ‘cover up’ of former president’s decline, White House says
  • DOGE staffing shakeup as Elon Musk hangs up his hat, White House confirms
  • State Dept says DOGE’s changes will be permanent amid Musk’s departure

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (751)
    • Investing (2,211)
    • Politics (2,729)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.